{"id":1017271,"date":"2026-11-05T04:55:59","date_gmt":"2026-11-05T09:55:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/"},"modified":"2026-11-05T04:55:59","modified_gmt":"2026-11-05T09:55:59","slug":"neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/","title":{"rendered":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"
\n

MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar\u00ae <\/sup>TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement awards to fourteen non-executive employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics\u2019 Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient\u2019s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company\u2019s 2020 Inducement Incentive Plan.<\/p>\n

\n Restricted stock units (\u201cRSUs\u201d)\u00a0<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Name\u00a0<\/td>\nNumber of Inducement Plan RSUs\u00a0<\/td>\nVesting Schedule\u00a0<\/td>\n<\/tr>\n
Chad McCatherin<\/td>\n9,000<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Nicholas Trabucco<\/td>\n2,400<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Maya McClain<\/td>\n2,400<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Alexandra Germain<\/td>\n2,400<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Jackie Fennelly<\/td>\n9,000<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Pia Arellano\u00a0\u00a0<\/td>\n2,400<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Ashley Reindel<\/td>\n9,000<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Egette Indelele<\/td>\n2,400<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Allison Manzer<\/td>\n29,250<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Allison Manzer<\/td>\n15,000<\/td>\n1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date; 1\/3 on fourth anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Omar Saleh<\/td>\n9,000<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Alondra Pastrona<\/td>\n2,400<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Giana Berrios<\/td>\n2,400<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Michael Rosenfield<\/td>\n3,000<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Erin DiMarco<\/td>\n11,250<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Erin DiMarco<\/td>\n12,000<\/td>\n1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date; 1\/3 on fourth anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n<\/table>\n

\n About Neuronetics<\/strong>
\n
Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar\u00ae <\/sup>Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (TMS) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO\u00ae <\/sup>therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO\u00ae <\/sup>(esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (\u201cTRD\u201d) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1<\/sup><\/p>\n

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.<\/strong><\/p>\n

Neuronetics Contact:
Investors:
Mike Vallie\u00a0or\u00a0Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com<\/strong><\/a><\/p>\n

Media:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com<\/strong><\/a><\/p>\n

\n References<\/strong>
\n
\n 1<\/sup>\u00a0The effectiveness of SPRAVATO\u00ae <\/sup>in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO\u00ae<\/sup>\u00a0does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO\u00ae<\/sup>. For more important safety information about SPRAVATO\u00ae<\/sup>, please visit\u00a0spravatohcp.com<\/strong><\/a>.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar\u00ae TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement awards to fourteen non-executive employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics\u2019 Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient\u2019s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company\u2019s 2020 Inducement Incentive Plan. Restricted stock units (\u201cRSUs\u201d)\u00a0 Name\u00a0 Number of Inducement … <\/p>\n

Continue reading “Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1017271","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar\u00ae TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement awards to fourteen non-executive employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics\u2019 Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient\u2019s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company\u2019s 2020 Inducement Incentive Plan. Restricted stock units (\u201cRSUs\u201d)\u00a0 Name\u00a0 Number of Inducement … Continue reading "Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-05T09:55:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDUyMCM3OTQ2NTY4IzIxMTA0NDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-11-05T09:55:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\\\/\"},\"wordCount\":1055,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDUyMCM3OTQ2NTY4IzIxMTA0NDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\\\/\",\"name\":\"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDUyMCM3OTQ2NTY4IzIxMTA0NDA=\",\"datePublished\":\"2026-11-05T09:55:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDUyMCM3OTQ2NTY4IzIxMTA0NDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDUyMCM3OTQ2NTY4IzIxMTA0NDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/","og_locale":"en_US","og_type":"article","og_title":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar\u00ae TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement awards to fourteen non-executive employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics\u2019 Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient\u2019s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company\u2019s 2020 Inducement Incentive Plan. Restricted stock units (\u201cRSUs\u201d)\u00a0 Name\u00a0 Number of Inducement … Continue reading \"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-05T09:55:59+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDUyMCM3OTQ2NTY4IzIxMTA0NDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-11-05T09:55:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/"},"wordCount":1055,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDUyMCM3OTQ2NTY4IzIxMTA0NDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/","name":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDUyMCM3OTQ2NTY4IzIxMTA0NDA=","datePublished":"2026-11-05T09:55:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDUyMCM3OTQ2NTY4IzIxMTA0NDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDUyMCM3OTQ2NTY4IzIxMTA0NDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-16\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1017271"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017271\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1017271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1017271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1017271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}